Chronic obstructive pulmonary disease, or COPD, is one of the most common long-term lung diseases in the world. It makes breathing harder over time and often leads to hospitalizations and serious complications. Despite decades of research, COPD remains a leading cause of death worldwide. For many years, new drugs in the research pipeline came and went, often with great promise but disappointing results. Researchers kept asking the same question: why is COPD so resistant to new treatments?
In 2025, that story is finally starting to change. For the first time, a few new medications have shown clear, reproducible benefits, especially for certain groups of patients. Understanding why so many drugs have failed, and why some are now succeeding, helps explain where COPD care is heading and why the basics of treatment still matter most.
Why COPD Has Been So Hard to Treat
To understand why drug development for COPD has been so frustrating, it helps to know what the disease actually is and what it is not. COPD is not one single illness. It is an umbrella term for a group of overlapping problems that damage the lungs and make it difficult to exhale fully. Most people with COPD have some combination of chronic bronchitis, which causes mucus buildup and inflammation in the airways, and emphysema, which destroys the lung’s tiny air sacs where oxygen exchange occurs.
For some patients, airway inflammation is the main problem. For others, it is the loss of elasticity in lung tissue, frequent infections, or mucus that traps air and causes airway collapse. Smoking is still the most common cause worldwide, but even among people who quit smoking years ago, the lungs can still be impacted by COPD.
Because COPD has many biological impacts, no single treatment works for everyone. Most drugs tested in the past decade targeted either one narrow aspects of inflammation or a very broad set of targets. As we have learned more about COPD, it has become clear that COPD involves a mix of inflammatory types, some related to allergies but many driven by infection, smoke exposure, or chronic bacterial changes in the airways. As a result, drugs that revolutionized asthma care did not make much difference in COPD and new targeted approaches were needed.
The Long Road of Modest Progress
That does not mean there has been no progress. The last two decades brought major improvements in the inhaled medications that form the foundation of COPD treatment. Long-acting bronchodilators help relax the airway muscles, making it easier to breathe. Later, doctors began using “triple therapy” inhalers that combine three medicines: a steroid to reduce inflammation, and two bronchodilators that keep airways open. These combination inhalers have reduced flare-ups, improved breathing symptoms, and likely increased survival for people at higher risk.
A few oral or add-on drugs also showed benefits. Roflumilast, an anti-inflammatory pill, helps people with severe chronic bronchitis, though it can cause some side effects for certain people. Long-term use of the antibiotic azithromycin reduced the number of flare-ups in patients who had frequent episodes, but this too can cause side effects in certain patients.
Even with these gains, most new therapies that went through large clinical trials failed to deliver clear results. Medications designed to block specific inflammatory signals, such as those targeting IL-5, IL-33, or TSLP, often worked very well in asthma but did not improve COPD flare-ups or lung function. Researchers now believe these trials may have failed because they enrolled too broad a group of patients. Many participants did not have the “type” of COPD the drugs were designed to help. The result was disappointing averages that masked small benefits for select individuals.
Another challenge is that standard COPD care keeps getting better. Patients are more likely today to be on the right inhalers, have their vaccines up to date, and receive support to quit smoking. That means people in clinical trials now have fewer flare-ups overall, even those receiving placebo. While this is good news for patients, it makes it harder to show additional benefit from new drugs. A treatment that might have looked impressive fifteen years ago now has to prove it can improve outcomes on top of already strong baseline care.
What Is Finally Working
Despite these challenges, progress is happening. The biggest breakthrough in recent years comes from a type of biologic medicine, an injectable drug that targets specific immune pathways involved in inflammation. In 2024, one such medication became the first biologic ever approved by the U.S. Food and Drug Administration for COPD. It works by blocking two inflammatory signals, IL-4 and IL-13, that drive a particular kind of airway inflammation called “type 2 inflammation.” In large studies, patients with high blood levels of a certain inflammatory cell, the eosinophil, experienced about one-third fewer flare-ups per year and measurable improvements in lung function when the drug was added to standard inhaler therapy.
In 2025, another biologic targeting eosinophils showed positive results as well. Although the effect was smaller, it reinforced an important lesson: biologics can help COPD patients, but only those whose disease is driven by the right biological process. For the first time, COPD treatment is beginning to follow the principles of precision medicine, matching the therapy to the biology of the patient rather than to the symptoms alone.
A different kind of drug, one taken by nebulizer rather than injection, has also made headlines. The medication, known as ensifentrine, combines two mechanisms that help open airways and reduce inflammation. In clinical trials, it consistently improved breathing test results and reduced daily symptoms when used as an add-on to standard therapy. Although it only modestly affected flare-up rates, it marked the first approval of a new inhaled mechanism for COPD in nearly twenty years.
Lessons From a Decade of Trial and Error
The story of COPD drug development over the past decade offers several lessons. First, COPD is not a single disease. It is a set of overlapping biological patterns that require different treatment approaches. Second, improving everyday care, such as proper inhaler use, smoking cessation, and pulmonary rehabilitation, still does more for most patients than any new drug. Third, clinical trials must continue to focus on identifying and enrolling the right patients rather than assuming one drug will work for all.
Researchers have also learned that flare-ups in COPD are complex events. Many are triggered by infections or mucus blockages rather than inflammation alone. Blocking one inflammatory pathway cannot prevent a bacterial infection, and it may not reduce the airway damage caused by years of smoke exposure. Future studies may use imaging or biological markers measured in blood or mucus to identify patients who will respond best to a given treatment.
The Continuing Role of Standard Care
Even with new therapies, the foundation of COPD management remains the same. Every successful trial so far has included participants already receiving optimal inhaler therapy, regular follow-up, and education about inhaler technique and adherence. Non-drug treatments also remain essential. Pulmonary rehabilitation programs help patients strengthen their breathing muscles and improve exercise tolerance. Vaccinations reduce the risk of serious infections that can worsen COPD. Oxygen therapy prolongs survival for those with very low oxygen levels, while home-based ventilatory support can improve quality of life for people with chronic retention of carbon dioxide.
Airway-clearance devices and other home equipment can further support breathing in patients who produce excess mucus or experience frequent infections. Durable medical equipment providers help patients use these tools correctly and consistently, bridging the gap between hospital care and home management. Together, these strategies remain the backbone of COPD care and should always accompany any new therapy.
A More Hopeful Future
After years of challenge, COPD researchers finally have a reason to be optimistic. The recent successes with biologics and new inhaled drugs demonstrate that progress is possible when treatment targets align with the underlying biology of the disease. These results also remind us that breakthroughs are rarely sudden; they build on years of learning from what did not work.
COPD will always be a complex condition that requires personalized care. But for the first time, there is a clear path forward, one that combines precision medicine with strong foundational care and the growing ability to match the right treatment to the right patient. For the millions of people living with COPD, that shift represents something rare in chronic disease: genuine, evidence-based hope.
.jpg?width=1120&height=376&name=AD-EmailBanner-Clean%20Filters%20(09.16).jpg)
References
1. Lipson, David A., et al. "Once-daily single-inhaler triple versus dual therapy in patients with COPD." New England Journal of Medicine 378.18 (2018): 1671-1680.
2. Rabe, Klaus F., et al. "Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD." New England Journal of Medicine 383.1 (2020): 35-48.
3. Calverley, Peter MA, et al. "Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials." The Lancet 374.9691 (2009): 685-694.
4. Albert, Richard K., et al. "Azithromycin for prevention of exacerbations of COPD." New England Journal of Medicine 365.8 (2011): 689-698.
5. Criner, Gerard J., et al. "Benralizumab for the prevention of COPD exacerbations." New England Journal of Medicine 381.11 (2019): 1023-1034.
6. Menzies-Gow, Andrew, et al. "Tezepelumab in adults and adolescents with severe, uncontrolled asthma." New England Journal of Medicine 384.19 (2021): 1800-1809.
7. Rabe, Klaus F., et al. "AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD." ERJ open research 10.5 (2024).
8. Dransfield, Mark T., and Daiana Stolz. "Mepolizumab in COPD—If at First You Don’t Succeed." NEJM evidence 4.6 (2025): EVIDe2500080.
9. Martineau, Adrian R., et al. "Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs)." Thorax 70.5 (2015): 451-457.
10. Bhatt, Surya P., et al. "Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation." New England Journal of Medicine 390.24 (2024): 2274-2283.
11. Anzueto, A., Barjaktarevic, I. Z., Siler, T. M., Rheault, T., Bengtsson, T., Rickard, K., & Sciurba, F. (2023). Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). American journal of respiratory and critical care medicine, 208(4), 406-416.
12. Andreas, Stefan et al. “Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression.” Respiratory research vol. 20,1 186. 16 Aug. 2019, doi:10.1186/s12931-019-1163-2
LEGAL DISCLAIMER: Material in this newsletter is provided for general health education and informational purposes and to provide references to other resources only; it may not apply to you as an individual. While Apria Healthcare believes that the information provided through this communication is accurate and reliable, Apria Healthcare cannot and does not make any such guarantee. It is not intended to be a replacement for professional medical advice, evaluation, diagnosis, services or treatment (collectively, “medical treatment”). Please see your healthcare provider for medical treatment related to you and your specific health condition(s). Never disregard medical advice or delay seeking medical care because of something you have read on or accessed through this website. Reading this newsletter should not be construed to mean that you have a healthcare provider/patient relationship.
.png)
